Blog Archives

Regulating AI

From Bench to Bedside: The Role of Science in Treating a Deadly Disease

The Transcriptional Legacy of Developmental Stochasticity

Personalized medicine is personal – moderator

Matt Might is an active advisor to the newly established Undiagnosed Disease Network Coordinating Center at Harvard University. He is passionate about patient-driven precision medicine, accelerating drug development in rare diseases, and bending the cost curve in medical research with computation and social media. He recently co-authored a white paper for the President’s precision medicine initiative.

Cancer, Early Tumor Diagnosis and Tumor DNA moderator

Kevin Davies is the founding editor of Bio-IT World and Nature Genetics, and the author of The $1,000 Genome (Free Press, 2010), an account of the revolution in DNA sequencing technologies, personal genomics, and personalized medicine.

2019 GoldLab Symposium Closing Remarks

Dr. Larry Gold is the Founder and Chairman Emeritus of the Board, and former CEO of SomaLogic. Prior to SomaLogic, he also founded and was the Chairman of NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.

Welcoming Remarks

Dr. Larry Gold is the Founder and Chairman Emeritus of the Board, and former CEO of SomaLogic. Prior to SomaLogic, he also founded and was the Chairman of NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.

Cry Havoc

Truly Personalized Medicines for Ultra-Rare Diseases: New Opportunities in Genomic Medicine

Why Would Anyone Study Rare Diseases?